Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell Liu

Showing results (31-40 of 93) with videos related to

Pageof 10
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 22, 2019
Cross-modality applicability of rectal normal tissue complication probability models from photon- to proton-based radiotherapyJesper Pedersen, Stella Flampouri, Curtis Bryant, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 3, 2018
The TEACHH model to predict life expectancy in patients presenting for palliative spine radiotherapy: external validation and comparison with alternate modelsMaryam Dosani, Scott Tyldesley, Brendan Bakos, et al.
Cureus|October 1, 2020
Comparison of Rapid to Standard Volumetric Modulated Arc Therapy for Palliative Radiotherapy in Lung Cancer PatientsDavid Y Mak, Ian Fraser, Robynn Ferris, et al.
Cancer|January 3, 2013
Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancerW James Morris, Mira Keyes, Ingrid Spadinger, et al.
Journal of Applied Clinical Medical Physics|March 30, 2023
In-vivo quality assurance of dynamic tumor tracking (DTT) for liver SABR using EPID imagesMaryam Rostamzadeh, Kurt Luchka, Roy Ma, et al.
Acta Oncologica (Stockholm, Sweden)|September 14, 2010
Normal Tissue Complication Probability (NTCP) modeling of late rectal bleeding following external beam radiotherapy for prostate cancer: A Test of the QUANTEC-recommended NTCP modelMitchell Liu, Vitali Moiseenko, Alexander Agranovich, et al.
The Canadian Journal of Urology|September 6, 2007
What is the optimal duration of androgen deprivation therapy in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/ml?Eric Berthelet, Tom Pickles, Pauline T Truong, et al.
International Journal of Radiation Oncology, Biology, Physics|November 15, 2011
Biochemical control with radiotherapy improves overall survival in intermediate and high-risk prostate cancer patients who have an estimated 10-year overall survival of >90%Christopher Herbert, Mitchell Liu, Scott Tyldesley, et al.
Annals of Translational Medicine|November 26, 2020
Dose matters for stereotactic body radiotherapy for early stage non-small cell lung cancerChristian C Okoye, C Jane Cho, Mitchell Liu, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|December 3, 2024
An Evaluation of the Usage of Internet Resources by Patients with Lung CancerSandy Lum-Wang, Paris-Ann Ingledew, Hannah Carolan, et al.
Pageof 10

Showing results (31-40 of 93) with videos related to

Sort By:
Pageof 10
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 22, 2019
Cross-modality applicability of rectal normal tissue complication probability models from photon- to proton-based radiotherapyJesper Pedersen, Stella Flampouri, Curtis Bryant, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 3, 2018
The TEACHH model to predict life expectancy in patients presenting for palliative spine radiotherapy: external validation and comparison with alternate modelsMaryam Dosani, Scott Tyldesley, Brendan Bakos, et al.
Cureus|October 1, 2020
Comparison of Rapid to Standard Volumetric Modulated Arc Therapy for Palliative Radiotherapy in Lung Cancer PatientsDavid Y Mak, Ian Fraser, Robynn Ferris, et al.
Cancer|January 3, 2013
Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancerW James Morris, Mira Keyes, Ingrid Spadinger, et al.
Journal of Applied Clinical Medical Physics|March 30, 2023
In-vivo quality assurance of dynamic tumor tracking (DTT) for liver SABR using EPID imagesMaryam Rostamzadeh, Kurt Luchka, Roy Ma, et al.
Acta Oncologica (Stockholm, Sweden)|September 14, 2010
Normal Tissue Complication Probability (NTCP) modeling of late rectal bleeding following external beam radiotherapy for prostate cancer: A Test of the QUANTEC-recommended NTCP modelMitchell Liu, Vitali Moiseenko, Alexander Agranovich, et al.
The Canadian Journal of Urology|September 6, 2007
What is the optimal duration of androgen deprivation therapy in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/ml?Eric Berthelet, Tom Pickles, Pauline T Truong, et al.
International Journal of Radiation Oncology, Biology, Physics|November 15, 2011
Biochemical control with radiotherapy improves overall survival in intermediate and high-risk prostate cancer patients who have an estimated 10-year overall survival of >90%Christopher Herbert, Mitchell Liu, Scott Tyldesley, et al.
Annals of Translational Medicine|November 26, 2020
Dose matters for stereotactic body radiotherapy for early stage non-small cell lung cancerChristian C Okoye, C Jane Cho, Mitchell Liu, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|December 3, 2024
An Evaluation of the Usage of Internet Resources by Patients with Lung CancerSandy Lum-Wang, Paris-Ann Ingledew, Hannah Carolan, et al.
Pageof 10